胶质母细胞瘤国际诊疗指南比较评价

Comparison and Evaluation of International Practice Guidelines for the Management of Glioblastoma Multiforme

胶质母细胞瘤是最常见的WHOIV级恶性胶质瘤，其特点是基因不稳定，临床特性难预测。尽管手术、放化疗等治疗手段不断进步，其预后仍然很差，中位生存期只有12～14个月。笔者从数据库和网络共检索到7个近年来不同国家发表的胶质母细胞瘤治疗指南或共识，结果显示，手术切除联合放疗和化疗仍然是胶质母细胞瘤的主要治疗手段，但是各国指南仍存在一些细节上的差异，如分子指标检测、化疗方案、复发后治疗方案等。本文通过对多国治疗指南比较，旨在为我国胶质母细胞瘤患者的治疗提供参考。

Glioblastoma multiforme （GBM） is the most common form of WHO grade Ⅳ malignant glioma, characterized by genetic instability and unpredictable clinical behavior. Despite of the advances in surgery, chemotherapy, and radiation therapy, the prognosis for glioblastomas remains poor, with median overall survival of 12- 14 months. The author assessed the latest development through comparison of practice guidelines or recommendations for management of glioblastoma multiforme from different countries. Seven practice guidelines and recommendations were acquired through different database and internet. The outcomes from comparison of the 7 guidehnes showed that neurosurgical resection combined with radiotherapy and chemotherapy was still the standard treatment for glioblastoma multiforme, but there were still some differences in details of guidelines from different countries, such as molecular analysis, chemotherapy agent, and management for recurrence. Through the comparison of these guidelines, reference will be provided for Chinese patients with glioblastoma.